SCHEMBL23217501

SCHEMBL23217501

CC(O)c1cc(Br)c2occc2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UGT2B7 P16662 1/20 0.38
BRD4 O60885 1/20 0.32
BRD2 P25440 1/20 0.32
CREBBP Q92793 1/20 0.32
CA9 Q16790 1/20 0.31
KDM4E B2RXH2 1/20 0.31
POLB P06746 1/20 0.31
MAPT P10636 1/20 0.31
HSD17B10 Q99714 1/20 0.31
HTR2A P28223 1/20 0.30
HTR2C P28335 1/20 0.30
HTR2B P41595 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2D6 P10635 1/20 0.30
CYP2A6 P11509 1/20 0.30
TSHR P16473 1/20 0.30
MAOA P21397 1/20 0.30
ACHE P22303 1/20 0.30
PDE4A P27815 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hexane SCHEMBL23217895 0.91 PTPN1 (0.33) UGT2B7CA9KDM4EMAOA
SCHEMBL3310919 0.77 CYP3A4 (0.42) UGT2B7KDM4EHSD17B10CYP1A2CYP3A4
SCHEMBL23217701 0.75 FFAR1 (0.35) CA9
SCHEMBL4153132 0.72 GABRA1 (0.37) CA9KDM4EPOLBMAPTHSD17B10
SCHEMBL23217832 0.72 MAOB (0.35) CA9KDM4EPOLBMAPTHSD17B10
SCHEMBL30010699 0.72 MAOB (0.35) CA9KDM4EPOLBMAPTHSD17B10
SCHEMBL2259316 0.72 ESR2 (0.47) KDM4EMAPTMAPK1
SCHEMBL2463440 0.72 MAOB (0.45) KDM4EPOLBMAPTHSD17B10CYP1A2
SCHEMBL23217823 0.72 CA9 (0.35) CA9KDM4EPOLBMAPTHSD17B10
SCHEMBL16426152 0.71 GPR35 (0.37) CYP1A2CYP3A4CYP2D6CYP2A6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250275991-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-09-04 US disclosed
CN-114555570-B Oral complement factor D inhibitors 拜奥克里斯特制药公司 2024-09-13 CN disclosed
WO-2023066357-A1 FUSED CYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF 江苏恒瑞医药股份有限公司 2023-04-27 WO disclosed
EP-4041717-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114555570-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-27 CN disclosed
WO-2021072156-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072156-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250275991-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB UGT2B7 1677/4885BRD4 4702/4885BRD2 3717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.